169 related articles for article (PubMed ID: 21072892)
1. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease.
Salama H; Zekri AR; Bahnassy AA; Medhat E; Halim HA; Ahmed OS; Mohamed G; Al Alim SA; Sherif GM
World J Gastroenterol; 2010 Nov; 16(42):5297-305. PubMed ID: 21072892
[TBL] [Abstract][Full Text] [Related]
2. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease.
Salama H; Zekri AR; Medhat E; Al Alim SA; Ahmed OS; Bahnassy AA; Lotfy MM; Ahmed R; Musa S
Stem Cell Res Ther; 2014 May; 5(3):70. PubMed ID: 24886681
[TBL] [Abstract][Full Text] [Related]
3. REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial.
King A; Barton D; Beard HA; Than N; Moore J; Corbett C; Thomas J; Guo K; Guha I; Hollyman D; Stocken D; Yap C; Fox R; Forbes SJ; Newsome PN
BMJ Open; 2015 Mar; 5(3):e007700. PubMed ID: 25795699
[TBL] [Abstract][Full Text] [Related]
4. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
[TBL] [Abstract][Full Text] [Related]
5. CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation.
Jaime-Pérez JC; Guillermo-Villanueva VA; Méndez-Ramírez N; Chapa-Rodríguez A; Gutiérrez-Aguirre H; Gómez-Almaguer D
Transfusion; 2009 Nov; 49(11):2390-4. PubMed ID: 19903294
[TBL] [Abstract][Full Text] [Related]
6. Autologous mobilized peripheral blood CD34(+) cell infusion in non-viral decompensated liver cirrhosis.
Sharma M; Rao PN; Sasikala M; Kuncharam MR; Reddy C; Gokak V; Raju B; Singh JR; Nag P; Nageshwar Reddy D
World J Gastroenterol; 2015 Jun; 21(23):7264-71. PubMed ID: 26109814
[TBL] [Abstract][Full Text] [Related]
7. CD133+CD34+ and CD133+CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation.
Camacho Villa AY; Reyes Maldonado E; Montiel Cervantes LA; Vela Ojeda J
Transfus Apher Sci; 2012 Jun; 46(3):239-44. PubMed ID: 22386660
[TBL] [Abstract][Full Text] [Related]
8. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency.
Zekri AR; Salama H; Medhat E; Musa S; Abdel-Haleem H; Ahmed OS; Khedr HA; Lotfy MM; Zachariah KS; Bahnassy AA
Stem Cell Res Ther; 2015 Jun; 6(1):118. PubMed ID: 26062731
[TBL] [Abstract][Full Text] [Related]
9. Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial.
Andreone P; Catani L; Margini C; Brodosi L; Lorenzini S; Sollazzo D; Nicolini B; Giordano R; Montemurro T; Rizzi S; Dan E; Giudice V; Viganò M; Casadei A; Foschi FG; Malvi D; Bernardi M; Conti F; Lemoli RM
Dig Liver Dis; 2015 Dec; 47(12):1059-66. PubMed ID: 26427587
[TBL] [Abstract][Full Text] [Related]
10. Transplantation of purified autologous leukapheresis-derived CD34+ and CD133+ stem cells for patients with chronic spinal cord injuries: long-term evaluation of safety and efficacy.
Al-Zoubi A; Jafar E; Jamous M; Al-Twal F; Al-Bakheet S; Zalloum M; Khalifeh F; Radi SA; El-Khateeb M; Al-Zoubi Z
Cell Transplant; 2014; 23 Suppl 1():S25-34. PubMed ID: 25372344
[TBL] [Abstract][Full Text] [Related]
11. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution.
Goussetis E; Manginas A; Koutelou M; Peristeri I; Theodosaki M; Kollaros N; Leontiadis E; Theodorakos A; Paterakis G; Karatasakis G; Cokkinos DV; Graphakos S
Stem Cells; 2006 Oct; 24(10):2279-83. PubMed ID: 16794269
[TBL] [Abstract][Full Text] [Related]
12. Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting.
Jaime-Pérez JC; Hernández-Alcántara AE; Méndez-Ramírez N; Vázquez-Garza E; Cantú-Rodríguez OG; Gómez-Almaguer D
Transfusion; 2009 Mar; 49(3):532-5. PubMed ID: 19243545
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor.
Freund D; Oswald J; Feldmann S; Ehninger G; Corbeil D; Bornhäuser M
Cell Prolif; 2006 Aug; 39(4):325-32. PubMed ID: 16872366
[TBL] [Abstract][Full Text] [Related]
14. CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells.
Kobari L; Giarratana MC; Pflumio F; Izac B; Coulombel L; Douay L
J Hematother Stem Cell Res; 2001 Apr; 10(2):273-81. PubMed ID: 11359674
[TBL] [Abstract][Full Text] [Related]
15. [Expression of AC133 vs. CD34 in acute childhood leukemias].
Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
[TBL] [Abstract][Full Text] [Related]
16. Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis.
Nikeghbalian S; Pournasr B; Aghdami N; Rasekhi A; Geramizadeh B; Hosseini Asl SM; Ramzi M; Kakaei F; Namiri M; Malekzadeh R; Vosough Dizaj A; Malek-Hosseini SA; Baharvand H
Arch Iran Med; 2011 Jan; 14(1):12-7. PubMed ID: 21194255
[TBL] [Abstract][Full Text] [Related]
17. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases.
Salama H; Zekri AR; Zern M; Bahnassy A; Loutfy S; Shalaby S; Vigen C; Burke W; Mostafa M; Medhat E; Alfi O; Huttinger E
Cell Transplant; 2010; 19(11):1475-86. PubMed ID: 20587151
[TBL] [Abstract][Full Text] [Related]
18. Stem cell therapy for the broken heart: mini-organ transplantation.
Mansour S; Roy DC; Lemieux B; Ouellet C; Stevens LM; Noiseux N
Transplant Proc; 2009 Oct; 41(8):3353-7. PubMed ID: 19857748
[TBL] [Abstract][Full Text] [Related]
19. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study.
Lang P; Schumm M; Greil J; Bader P; Klingebiel T; Müller I; Feuchtinger T; Pfeiffer M; Schlegel PG; Niethammer D; Handgretinger R
Klin Padiatr; 2005; 217(6):334-8. PubMed ID: 16307419
[TBL] [Abstract][Full Text] [Related]
20. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Hicks C; Wong R; Manoharan A; Kwan YL
Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
